Lady Gaga Partners with Pfizer to Raise Migraine Awareness
June is Migraine and Headache Awareness Month, and in keeping with this year’s theme, “Educate Yourself, Educate Others,” Pfizer is partnering with Lady Gaga to raise awareness of this often-misunderstood disease.
Affecting about 40 million people in the United States and one billion people globally, migraine is a debilitating and recurrent neurological disease. In fact, according to one study, migraine is considered the second-most disabling condition in the world, following low back pain.1,2
An Academy Award®, Golden Globe® Award, and 13-time Grammy® Award-winning actress and philanthropist, Lady Gaga was diagnosed with migraine when she was 14 years old, and it has had a profound impact on her life.
“Lady Gaga’s story is a powerful reminder of how significantly migraine affects the lives of so many people,” says Angela Lukin, Global Primary Care and U.S. President, Pfizer. “We believe that this collaboration will help raise awareness of this often ‘silent’ disease and inspire those living with migraine to have conversations with their healthcare providers about the best way to manage their condition.”
By showcasing Lady Gaga’s experience, Pfizer hopes to help people better understand the effect migraine can have on their lives and to show people living with the disease that they are not alone.
References
- Buse et al. Burden of Illness Among People with Migraine and ≥ 4 Monthly Headache Days While Using Acute and/or Preventive Prescription Medications for Migraine. Journal of Managed Care & Specialty Pharmacy. 2020;26(10):1334-1343.
- GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018;17(11):954-976.
07.05.2023 Business Leadership Vaccines Pfizer’s Social Media Round-Up—June Edition 06.30.2023 Cancer Employees Partnerships Pfizer Joins Annual Brunch Run to Support Cancer Support Non-Profit Imerman Angels 06.30.2023 Vaccines Pfizer and the European Commission Enter into Manufacturing Reservation Agreement for mRNA-based Vaccines to Help Protect Against Future Pandemics 06.23.2023 Vaccines Pfizer and BioNTech Submit Applications to U.S. FDA for Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine 06.23.2023 Vaccines Pfizer and BioNTech Initiate Application to European Medicines Agency for Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine